The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Lifecore Biomedical's Revenue for the
three
months ended in Mar. 2026 was $23.19 Mil. Lifecore Biomedical's average Accounts Receivable for the
three
months ended in Mar. 2026 was $22.80 Mil.
Hence, Lifecore Biomedical's Receivables Turnover for the
three
months ended in Mar. 2026 was 1.02.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Lifecore Biomedical Receivables Turnover Related Terms
Lifecore Biomedical Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Lifecore Biomedical's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LFCR vs ANIK, DERM, ASRT: Receivables Turnover Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Lifecore Biomedical's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lifecore Biomedical Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Lifecore Biomedical's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Lifecore Biomedical's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lifecore Biomedical (LFCR) has a Receivables Turnover of 1.02 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Lifecore Biomedical and its competitors. According to the industry distribution chart, Lifecore Biomedical ranks #671 out of 947 companies in the Drug Manufacturers industry, placing it in the top 70.9%.
Is Lifecore Biomedical's Receivables Turnover too high?
Lifecore Biomedical's current Receivables Turnover is 1.02. The Drug Manufacturers industry median Receivables Turnover is 5.07. Lifecore Biomedical's value of 1.02 is 79.9% below this industry median. Based on the distribution chart, Lifecore Biomedical ranks #671 out of 947 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Lifecore Biomedical has a GF Score™ of 55/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lifecore Biomedical's Receivables Turnover compare to ANIK and DERM?
According to the Drug Manufacturers industry distribution chart, Lifecore Biomedical ranks #671 out of 947 companies for Receivables Turnover. This places Lifecore Biomedical in the lower half of its industry. The industry median Receivables Turnover is 5.07. Lifecore Biomedical's value of 1.02 is 79.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.07, based on 947 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lifecore Biomedical's current Receivables Turnover of 1.02 is 79.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Lifecore Biomedical and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lifecore Biomedical's current Receivables Turnover is 1.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lifecore Biomedical stock overvalued right now?
Based on GuruFocus' analysis, Lifecore Biomedical (LFCR) is currently considered Modestly Undervalued. The stock's GF Value™ is $6.49, compared to a current price of $4.76 — trading 26.7% below its estimated fair value. The current Receivables Turnover is 1.02 and 79.9% below the Drug Manufacturers industry median of 5.07. Lifecore Biomedical's overall GF Score™ is 55/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Lifecore Biomedical (LFCR), the current Receivables Turnover is 1.02 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lifecore Biomedical (LFCR) Overvalued in 2026?
Based on GuruFocus' analysis, Lifecore Biomedical stock appears to be undervalued.
The current stock price of $4.76 is trading 26.7% below its estimated GF Value™ of $6.49.
GuruFocus considers Lifecore Biomedical to be Modestly Undervalued.
Key valuation signals for LFCR:
Receivables Turnover: 1.02
GF Value™: $6.49 vs. price of $4.76 (26.7% below fair value)
Industry Position: 79.9% below the Drug Manufacturers median (#671 of 947)
No single metric tells the full story. See the LFCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.
55GF Score
Get the complete analysis for LFCR
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LFCR has been successfully added to your 
